NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, Forecast & News

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.08. During the same quarter last year, the firm earned ($0.24) EPS. View Spectrum Pharmaceuticals' Earnings History.

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Spectrum Pharmaceuticals.

5 equities research analysts have issued 12 month target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $21.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $13.20 in the next twelve months. This suggests a possible upside of 423.8% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

Press coverage about SPPI stock has been trending very negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Spectrum Pharmaceuticals earned a news impact score of -3.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals saw a decline in short interest in February. As of February 14th, there was short interest totalling 10,250,000 shares, a decline of 21.5% from the January 30th total of 13,050,000 shares. Based on an average daily trading volume, of 2,490,000 shares, the days-to-cover ratio is currently 4.1 days. Approximately 10.4% of the shares of the company are short sold. View Spectrum Pharmaceuticals' Current Options Chain.

Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Exelixis (EXEL), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Zynerba Pharmaceuticals (ZYNE), Amicus Therapeutics (FOLD), Verastem (VSTM), Bausch Health Companies (BHC) and AT&T (T).

Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.29%), Renaissance Technologies LLC (2.48%), Geode Capital Management LLC (1.36%), FMR LLC (1.23%), Bank of New York Mellon Corp (1.12%) and ArrowMark Colorado Holdings LLC (0.95%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

SPPI stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, FMR LLC, Sargent Investment Group LLC, Sargent Investment Group LLC, Panagora Asset Management Inc., Citigroup Inc., UBS Group AG and Arizona State Retirement System. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Insider Buying and Selling for Spectrum Pharmaceuticals.

SPPI stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Alpine Global Management LLC, Great West Life Assurance Co. Can, Geode Capital Management LLC, Bank of New York Mellon Corp and Teza Capital Management LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SPPI stock can currently be purchased for approximately $2.52.

Spectrum Pharmaceuticals has a market capitalization of $284.68 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]